Intracellular boosting of HIV protease inhibitors through inhibition of transport - a novel strategy for potentiating HIV therapy - Intracellular Boosting of HIV Protease Inhibitors
- Conditions
- This study is to evaluate the intracellular boosting effect of furosemide and dipyridamole of the HIV protease inhibitors in HIV positive patients.
- Registration Number
- EUCTR2008-002627-90-GB
- Lead Sponsor
- Royal Liverpool and Broadgreen University Hospitals NHS Trust
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 100
•The ability to understand and sign a written informed consent form, prior to participation in any screening procedures and must be willing to comply with all study requirements.
•Male or female patients
•= 18 years
•HIV positive
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
•History of drug sensitivity or drug allergy to lopinavir, ritonavir, furosemide, dipyridamole
•< 18 years
•Pregnant or lactating women
•Women of childbearing age unless using appropriate contraception
•CD4 < 100 x 106.l-1
•Viral load > 5000 copies
•Anaemia (Hb < 10.0 g.dl-1)
•Severe coronary artery disease
•Unstable angina
•Recent myocardial infarction or haemodynamic instability
•Severe hypotension (systolic < 100 mm Hg or diastolic < 60 mm Hg)
•Hypovolaemia or dehydration
•Renal dysfunction (eGFR < 70 ml/min/1.73 m2)
•Severe hypokalaemia (K+ < 3.0 mmol.l-1)
•Severe hyponatraemia (Na+ < 130 mmol.l-1)
•Men with symptomatic urinary outflow obstruction
•Any known bleeding disorders
•INR < 1.5
•Platelets < 100 109.l-1
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method